GLPwatch
Papers (9189)
Page 87 of 154, ranked by citation count.
- Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.
- Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
- The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
- Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
- MiR-7, miR-9 and miR-375 contribute to effect of Exendin-4 on pancreatic β-cells in high-fat-diet-fed mice.
- Pro-healing impact of liraglutide on skin wounds in normoglycemic mice.
- Exendin-4 protects the hearts of rats from ischaemia/reperfusion injury by boosting antioxidant levels and inhibition of JNK/p<sup>66</sup> Shc/NADPH axis.
- Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.
- A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo.
- Semaglutide and bariatric surgery induce distinct changes in the composition of mouse white adipose tissue.
- Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy.
- Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.
- [Exendin-4 alleviates diabetic cardiomyopathy in mice by regulating Sirt1/PGC1α].
- Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4.
- Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.
- Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
- Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY<sub>3-36</sub>, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.
- Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
- The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
- Sphingosine kinase 1-interacting protein is a novel regulator of glucose-stimulated insulin secretion.
- Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells.
- The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.
- Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice.
- Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells.
- Semaglutide and heart failure: Updated meta-analysis.
- Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial.
- Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.
- Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
- Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers.
- Semaglutide injection for the treatment of adults with type 2 diabetes.
- The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
- Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
- Glucagon-like peptide-1 receptor agonism and end-organ protection.
- IDegLira for type 2 diabetes: a systematic review and meta-analysis.
- Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival.
- Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.
- Liraglutide protects from renal damage via Akt-mTOR pathway in rats with diabetic kidney disease.
- Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.
- Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.
- Regional gastrointestinal pH profile is altered in patients with type 1 diabetes and peripheral neuropathy.
- Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis.
- Novel insights into the augmented effect of curcumin and liraglutide in ameliorating cisplatin-induced nephrotoxicity in rats: Effects on oxidative stress, inflammation, apoptosis and pyroptosis via GSK-3β.
- <sup>68</sup>Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma.
- Molecularly engineered islet cell clusters for diabetes mellitus treatment.
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
- Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.
- Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery.
- Exendin-4 attenuates brain death-induced liver damage in the rat.
- Xenotransplantation of exendin-4 gene transduced pancreatic islets using multi-component (alginate, poly-L-lysine, and polyethylene glycol) microcapsules for the treatment of type 1 diabetes mellitus.
- Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.
- Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
- Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
- Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.
- Hypothalamic GABAergic Neurons Expressing Cellular Retinoic Acid Binding Protein 1 (CRABP1) Are Sensitive to Metabolic Status and Liraglutide in Male Mice.
- Managing bile acid diarrhea: aspects of contention.
- Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice.
- Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.
- Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.
- Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.
- Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.